<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Data Brief</journal-id><journal-id journal-id-type="iso-abbrev">Data Brief</journal-id><journal-title-group><journal-title>Data in Brief</journal-title></journal-title-group><issn pub-type="epub">2352-3409</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29214202</article-id><article-id pub-id-type="pmc">5712048</article-id><article-id pub-id-type="publisher-id">S2352-3409(17)30449-3</article-id><article-id pub-id-type="doi">10.1016/j.dib.2017.09.018</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology, Toxicology and Pharmaceutical Science</subject></subj-group></article-categories><title-group><article-title>Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Haass-Koffler</surname><given-names>Carolina L.</given-names></name><email>carolina_haass-koffler@brown.edu</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Goodyear</surname><given-names>Kimberly</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Long</surname><given-names>Victoria M.</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Tran</surname><given-names>Harrison H.</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Loche</surname><given-names>Antonella</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Cacciaglia</surname><given-names>Roberto</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Swift</surname><given-names>Robert M.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Leggio</surname><given-names>Lorenzo</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA</aff><aff id="aff0010"><label>b</label>Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA</aff><aff id="aff0015"><label>c</label>Laboratorio CT, San Remo, Italy</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. <email>carolina_haass-koffler@brown.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>17</day><month>9</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>12</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>17</day><month>9</month><year>2017</year></pub-date><volume>15</volume><fpage>407</fpage><lpage>413</lpage><history><date date-type="received"><day>29</day><month>7</month><year>2017</year></date><date date-type="rev-recd"><day>6</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>12</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Authors</copyright-statement><copyright-year>2017</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="ab0010"><p>The data in this article outline the methods used for the administration of GET 73 in the first time-in-human manuscript entitled &#x0201c;Phase I randomized clinical trial for the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy male volunteers&#x0201d; (Haass-Koffler et al., 2017) <xref rid="bib1" ref-type="bibr">[1]</xref>. Data sets are provided in two different manners. The first series of tables provided includes procedural information about the experiments conducted. The next series of tables provided includes Pharmacokinetic (PK) parameters for GET 73 and its main metabolite MET 2. This set of data is comprised by two experiments: <italic>Experiment 1</italic> references a single ascending dose administration of GET 73 and <italic>Experiment 2</italic> references a repeated ascending dose administration of GET 73.</p></abstract><kwd-group id="keys0005"><title>Keywords</title><kwd>Glutamate receptor subtype 5 (mGlu5)</kwd><kwd>Allosteric modulator</kwd><kwd>GET 73</kwd><kwd>Safety</kwd><kwd>Tolerability</kwd></kwd-group></article-meta></front><body><p id="p0005"><bold>Specifications Table</bold><table-wrap id="t0075" position="float"><alt-text id="at0075">Table</alt-text><table frame="hsides" rules="groups"><tbody><tr><td>Subject area</td><td>Pharmaceutical Sciences</td></tr><tr><td>More specific subject area</td><td>Phase I randomized clinical trial, first-time-in-humans, dose escalation</td></tr><tr><td>Type of data</td><td>Table</td></tr><tr><td>How data was acquired</td><td>Clinical assessments and blood sampling</td></tr><tr><td>Data format</td><td>Filtered</td></tr><tr><td rowspan="2">Experimental factors</td><td>The trial was approved by the Medicine and Healthcare products</td></tr><tr><td>Regulatory Agency (MHRA). Participants (<italic>N</italic> = 80, total across the two experiments) are administered GET 73 either as single escalation dose [10, 30, 100, 300, 450, or 600-mg) or a repeated dose (100, 300, 450, 450-mg (twice a day)] over 14 days</td></tr><tr><td>Experimental features</td><td>This was a double-blind, placebo-controlled, ascending dose, Phase I randomized clinical trial conducted in healthy male volunteers in two Experiments. The primary aim was to look at the safety and tolerability of GET 73. In addition, preliminary pharmacokinetic data on GET 73 and its main metabolite MET 2 were collected</td></tr><tr><td>Data source location</td><td>LCG Bioscience, Cambridge, UK</td></tr><tr><td>Data accessibility</td><td>The data are available in this article</td></tr></tbody></table></table-wrap></p><p id="p0010"><bold>Value of the data</bold><list list-type="simple"><list-item id="u0005"><label>&#x02022;</label><p id="p0015">Data provides safe doses for administration of GET 73.</p></list-item><list-item id="u0010"><label>&#x02022;</label><p id="p0020">Data outlines the procedures tested for safe administration of GET 73 at safe doses in future study groups.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0025">Pharmacokinetic parameters were collected for GET 73 and MET 2 as reference data to evaluate the bioavailability of GET 73.</p></list-item></list></p><sec id="s0005"><label>1</label><title>Data</title><p id="p0030">The dataset presents an outline of the study and pharmacokinetic analytical data for GET 73: (N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide) (Haass-Koffler et al., 2017) <xref rid="bib1" ref-type="bibr">[1]</xref>. Pharmacokinetic data for MET 2: (4-oxo-4-{[(4-trifluoromethyl)benzyl]amino}butanoic acid), a main metabolite of GET 73, is also included in the data set. <xref rid="t0005" ref-type="table">Table 1</xref>, <xref rid="t0010" ref-type="table">Table 2</xref>, <xref rid="t0015" ref-type="table">Table 3</xref>, <xref rid="t0020" ref-type="table">Table 4</xref>, <xref rid="t0025" ref-type="table">Table 5</xref> present procedural outlines for the Phase I randomized clinical trial. <xref rid="t0030" ref-type="table">Table 6</xref>, <xref rid="t0035" ref-type="table">Table 7</xref>, <xref rid="t0040" ref-type="table">Table 8</xref>, <xref rid="t0045" ref-type="table">Table 9</xref>, <xref rid="t0050" ref-type="table">Table 10</xref> provide pharmacokinetic data for GET 73, while <xref rid="t0055" ref-type="table">Table 11</xref>, <xref rid="t0060" ref-type="table">Table 12</xref>, <xref rid="t0065" ref-type="table">Table 13</xref>, <xref rid="t0070" ref-type="table">Table 14</xref> provide pharmacokinetic data for MET 2.<table-wrap id="t0005" position="float"><label>Table 1</label><caption><p><italic>Experiment 1,</italic> single ascending dose schedule.</p></caption><alt-text id="at0005">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th><bold>Phase</bold></th><th align="center"><bold>Screening</bold></th><th align="center"><bold>Inpatient period</bold></th><th><bold>Study drug administration</bold></th><th align="center"><bold>Outpatient visit</bold></th><th align="center"><bold>Follow-up</bold></th></tr></thead><tbody><tr><td><bold>Days</bold></td><td align="center">&#x02212;21 to &#x02212;2</td><td align="center">&#x02212;1 to 3</td><td align="center">1</td><td align="center">3</td><td align="center">15</td></tr></tbody></table></table-wrap><table-wrap id="t0010" position="float"><label>Table 2</label><caption><p><italic>Experiment 2,</italic> multiple ascending dose schedule.</p></caption><alt-text id="at0010">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th><bold>Phase</bold></th><th><bold>Screening</bold></th><th><bold>Inpatient period</bold></th><th><bold>Study drug administration</bold></th><th><bold>Outpatient visits</bold></th><th><bold>Residency period</bold></th><th><bold>Follow-up</bold></th></tr></thead><tbody><tr><td><bold>Days</bold></td><td align="center">&#x02212;21 to &#x02212;2</td><td align="center">&#x02212;1 to 3</td><td align="center">1 to 14</td><td align="center">5, 7, 9, 11, and 13</td><td align="center">13 to 16</td><td align="center">28</td></tr></tbody></table></table-wrap><table-wrap id="t0015" position="float"><label>Table 3</label><caption><p><italic>Experiment 1,</italic> assessments and procedures.</p></caption><alt-text id="at0015">Table 3</alt-text><table frame="hsides" rules="groups"><tbody><tr><td align="left"><inline-graphic xlink:href="fx1.gif"/></td></tr></tbody></table></table-wrap><table-wrap id="t0020" position="float"><label>Table 4</label><caption><p><italic>Experiment 2,</italic> assessments and procedures.</p></caption><alt-text id="at0020">Table 4</alt-text><table frame="hsides" rules="groups"><tbody><tr><td align="left"><inline-graphic xlink:href="fx2.gif"/></td></tr></tbody></table></table-wrap><table-wrap id="t0025" position="float"><label>Table 5</label><caption><p>Clinical laboratory assessments.</p></caption><alt-text id="at0025">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th><bold>Clinical chemistry</bold></th><th><bold>Haematology</bold></th></tr></thead><tbody><tr><td>&#x003b3; Glutamyl Transferase</td><td>Haematocrit</td></tr><tr><td>Alanine Transaminase</td><td>Haemoglobin</td></tr><tr><td>Aspartate Transaminase</td><td/></tr><tr><td>Alkaline Phosphatase</td><td>Mean Corpuscular Haemoglobin</td></tr><tr><td>Potassium</td><td/></tr><tr><td>Sodium</td><td>Mean Corpuscular Hemoglobin Concentration</td></tr><tr><td>Calcium</td><td>Mean Cell Volume</td></tr><tr><td>Bilirubin &#x02013; Direct (only if Total Bilirubin was outside the normal range)</td><td>Platelet count</td></tr><tr><td>Bilirubin &#x02013; Total</td><td>Red Blood Cell count</td></tr><tr><td>Albumin</td><td>Urinalysis</td></tr><tr><td>Protein &#x02013; Total</td><td>pH</td></tr><tr><td>White Blood Cell count (1)</td><td>Leukocytes (2)</td></tr><tr><td>Creatinine</td><td>Nitrite</td></tr><tr><td>Glucose (fasting)</td><td>Glucose</td></tr><tr><td>Inorganic Phosphate</td><td>Ketones</td></tr><tr><td>Triglycerides</td><td>Protein (2)</td></tr><tr><td>Cholesterol</td><td>Blood (2)</td></tr><tr><td>Urea</td><td>Urine test for drugs of abuse</td></tr><tr><td>Uric Acid</td><td>AmphetaminesEcstasy</td></tr><tr><td>Serum virology</td><td>Barbiturates</td></tr><tr><td>Hepatitis B Core Antibody</td><td>Benzodiazepines</td></tr><tr><td>Hepatitis B Surface Antigen</td><td>Cannabis</td></tr><tr><td>Hepatitis C Virus</td><td>Cocaine</td></tr><tr><td>HIV-l / HIV-2</td><td>MethadoneOpiates</td></tr></tbody></table><table-wrap-foot><fn><p>1 White blood cell count included differential white blood cell count. 2 Direct microscopy was performed if the sample was positive for any of these parameters.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0030" position="float"><label>Table 6</label><caption><p><italic>Experiment 1,</italic> GET 73 Pharmacokinetics parameters: <italic>C</italic><sub><italic>max</italic></sub> (ng/mL), <italic>AUC</italic><sub><italic>0-t</italic></sub> (ng*h/mL) and <italic>t</italic><sub><italic>max</italic></sub> (h) by dose/treatment and day.</p></caption><alt-text id="at0030">Table 6</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Dose GET 73</th><th align="center"><italic>C</italic><sub><italic>max</italic></sub> (ng/mL)</th><th align="center"><italic>AUC</italic><sub><italic>0-t</italic></sub> (ng*h/mL)</th><th align="center"><italic>t</italic><sub><italic>max</italic></sub> (h)</th></tr></thead><tbody><tr><td>10-mg</td><td align="center">48.35 (27.47&#x02013;69.23)</td><td align="center">60.04 (25.97&#x02013;94.11)</td><td align="center">0.50 (0.5&#x02013;1.0)</td></tr><tr><td>30-mg</td><td align="center">309.67 (211.46&#x02013;407.88)</td><td align="center">387.36 (224.72&#x02013;550.01)</td><td align="center">0.50 (0.50&#x02013;1.02)</td></tr><tr><td>100-mg</td><td align="center">721.33 (250.65&#x02013;1192.01)</td><td align="center">1246.80 (690.63&#x02013;1802.98)</td><td align="center">0.75 (0.50&#x02013;1.50)</td></tr><tr><td>300-mg</td><td align="center">1384.67 (510.79&#x02013;2258.54)</td><td align="center">3624.01 (1451.26&#x02013;5796.77)</td><td align="center">0.75 (0.50&#x02013;1.50)</td></tr><tr><td>450-mg</td><td align="center">3891.67 (2442.82&#x02013;5340.52)</td><td align="center">6931.90 (3314.19&#x02013;10,549.62)</td><td align="center">0.50 (0.50&#x02013;1.00)</td></tr><tr><td>600-mg</td><td align="center">5015.0 (3061.38&#x02013;6968.62)</td><td align="center">13,338.25 (7495.02&#x02013;19,181.48)</td><td align="center">0.75 (0.50&#x02013;1.50)</td></tr></tbody></table><table-wrap-foot><fn><p>Results reported as <italic>M</italic> and lower to upper 95% (<italic>CI</italic>) and for <italic>t</italic><sub><italic>max</italic></sub> as median (min-max values).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0035" position="float"><label>Table 7</label><caption><p><italic>Experiment 2,</italic> GET 73 Pharmacokinetics parameters: <italic>C</italic><sub><italic>max</italic></sub> (ng/mL) by dose/treatment and day.</p></caption><alt-text id="at0035">Table 7</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Dose GET73</th><th align="center">Day 1 - single dose (ng/mL)</th><th align="center">Day 14 - repeated doses (ng/mL)</th></tr></thead><tbody><tr><td>100-mg</td><td align="center">368.17 (218.85&#x02013;517.48)</td><td align="center">302.67 (151.32&#x02013;454.02)</td></tr><tr><td>300-mg</td><td align="center">2660.33 (1348.94&#x02013;3971.73)</td><td align="center">2075.67 (1016.19&#x02013;3135.14)</td></tr><tr><td>450-mg</td><td align="center">3723.33 (2774.58&#x02013;4672.08)</td><td align="center">3161.83 (2089.28&#x02013;4234.39)</td></tr><tr><td>450-mg twice day</td><td align="center">3271.67 (2140.81&#x02013;4402.52)</td><td align="center">4055.00 (2587.33&#x02013;5522.67)</td></tr></tbody></table><table-wrap-foot><fn><p>Results reported as <italic>M</italic> and lower to upper 95% (<italic>CI</italic>).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0040" position="float"><label>Table 8</label><caption><p><italic>Experiment 2,</italic> GET 73 Pharmacokinetics parameters: <italic>t</italic><sub><italic>max</italic></sub> (h) by dose/treatment and day.</p></caption><alt-text id="at0040">Table 8</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Dose GET73</th><th align="center">Day 1 - single dose (h)</th><th align="center">Day 14 - repeated doses (h)</th></tr></thead><tbody><tr><td>100-mg</td><td align="center">1.00 (0.50&#x02013;1.50)</td><td align="center">1.00 (0.50&#x02013;1.50)</td></tr><tr><td>300-mg</td><td align="center">0.50 (0.50&#x02013;1.00)</td><td align="center">0.75 (0.50&#x02013;1.50)</td></tr><tr><td>450-mg</td><td align="center">1.00 (0.50&#x02013;1.53)</td><td align="center">1.00 (0.50&#x02013;1.50)</td></tr><tr><td>450-mg twice day</td><td align="center">0.75 (0.5&#x02013;2.05)</td><td align="center">0.75 (0.50&#x02013;1.50)</td></tr></tbody></table><table-wrap-foot><fn><p>Results reported as <italic>Median</italic> and minimum and maximum.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0045" position="float"><label>Table 9</label><caption><p><italic>Experiment 2,</italic> GET 73 Pharmacokinetics parameters: <italic>AUC</italic><sub><italic>0-t</italic></sub> (ng*h/mL) by dose/treatment and day.</p></caption><alt-text id="at0045">Table 9</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Dose GET73</th><th align="center">Day 1 - single dose (ng*h/mL)</th><th align="center">Day 14 - repeated doses (ng*h/mL)</th><th align="center">Ratio day 14/day1</th></tr></thead><tbody><tr><td>100-mg</td><td align="center">657.3 (382.67&#x02013;931.59)</td><td align="center">598.75 (369.52&#x02013;827.98)</td><td align="center">0.91</td></tr><tr><td>300-mg</td><td align="center">6348.74 (2297.78&#x02013;10,399.70)</td><td align="center">5938.89 (2193.79&#x02013;9684.00)</td><td align="center">0.94</td></tr><tr><td>450-mg</td><td align="center">8541.24 (6244.42&#x02013;10,838.07)</td><td align="center">8102.90 (4724.25&#x02013;11,481.55)</td><td align="center">0.95</td></tr><tr><td>450-mg twice day</td><td align="center">8639.29 (5811.59&#x02013;11,467.00)</td><td align="center">9704.90 (6053.12&#x02013;13,356.68)</td><td align="center">1.12</td></tr></tbody></table><table-wrap-foot><fn><p>Results reported as <italic>M</italic> and lower to upper 95% (<italic>CI</italic>).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0050" position="float"><label>Table 10</label><caption><p><italic>Experiment 2,</italic> GET 73 Pharmacokinetics parameters: <italic>C</italic><sub><italic>min</italic></sub> (ng/mL) by dose/treatment and day.</p></caption><alt-text id="at0050">Table 10</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Dose GET73</th><th align="center">Day 1 - single dose (ng/mL)</th><th align="center">Day 14 - repeated doses (ng/mL)</th></tr></thead><tbody><tr><td>100-mg</td><td align="center">0 (0&#x02013;0)</td><td align="center">0 (0&#x02013;0)</td></tr><tr><td>300-mg</td><td align="center">0.36 (&#x02212;0.35 to 1.07)</td><td align="center">0 (0&#x02013;0)</td></tr><tr><td>450-mg</td><td align="center">0.36 (&#x02212;0.35 to 1.07)</td><td align="center">0 (0&#x02013;0)</td></tr><tr><td>450-mg twice day</td><td align="center">49.99 (&#x02212;5.45 to 105.42)</td><td align="center">39.36(12.16&#x02013;66.57)</td></tr></tbody></table><table-wrap-foot><fn><p>Results reported as <italic>M</italic> and lower to upper 95% (<italic>CI</italic>).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0055" position="float"><label>Table 11</label><caption><p><italic>Experiment 2,</italic> MET 2 parameters: <italic>C</italic><sub><italic>max</italic></sub> (ng/mL) by dose/treatment and day.</p></caption><alt-text id="at0055">Table 11</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Dose GET73</th><th>Day 1 -single dose (ng/mL)</th><th>Day 14 - repeated doses (ng/mL)</th></tr></thead><tbody><tr><td>100-mg</td><td>1728.33 (1415.98&#x02013;2040.68)</td><td>1491.33 (1042.06&#x02013;1940.61)</td></tr><tr><td>300-mg</td><td>4193.33 (3550.43&#x02013;4836.23)</td><td>4511.67 (3828.91&#x02013;5194.42)</td></tr><tr><td>450-mg</td><td>6691.67 (5304.95&#x02013;8078.38)</td><td>6003.33 (5664.54&#x02013;6342.12)</td></tr><tr><td>450-mg twice day</td><td>7406.67 (6299.63&#x02013;8513.71)</td><td>8820.00 (7482.47&#x02013;10,157.53)</td></tr></tbody></table><table-wrap-foot><fn><p>Results reported as <italic>M</italic> and lower to upper 95% (<italic>CI</italic>).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0060" position="float"><label>Table 12</label><caption><p><italic>Experiment 2,</italic> MET 2 parameters: <italic>t</italic><sub><italic>max</italic></sub> (h) by dose/treatment and day.</p></caption><alt-text id="at0060">Table 12</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Dose GET73</th><th align="center">Day 1 - single dose (h)</th><th align="center">Day 14 - repeated doses (h)</th></tr></thead><tbody><tr><td>100-mg</td><td align="center">1.00 (0.50&#x02013;1.50)</td><td align="center">1.00 (0.50&#x02013;1.50)</td></tr><tr><td>300-mg</td><td align="center">1.00 (0.50&#x02013;1.50)</td><td align="center">1.50 (1.00&#x02013;2.00)</td></tr><tr><td>450-mg</td><td align="center">1.25 (1.00&#x02013;2.00)</td><td align="center">1.25 (1.00&#x02013;1.50)</td></tr><tr><td>450-mg twice day</td><td align="center">1.25 (1.05&#x02013;2.05)</td><td align="center">1.29 (1.00&#x02013;1.60)</td></tr></tbody></table><table-wrap-foot><fn><p>Results reported as <italic>Median</italic> and minimum and maximum.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0065" position="float"><label>Table 13</label><caption><p><italic>Experiment 2,</italic> MET 2 parameters: <italic>AUC</italic><sub><italic>0-t</italic></sub> (ng*h/mL) by dose/treatment and day.</p></caption><alt-text id="at0065">Table 13</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Dose GET73</th><th align="center">Day 1 - single dose (ng*h/mL)</th><th align="center">Day 14 - repeated doses (ng*h/mL)</th><th align="center">Ratio day 14/day1</th></tr></thead><tbody><tr><td>100-mg</td><td align="center">3934.30 (3373.35&#x02013;4495.25)</td><td align="center">3790.54 (3086.52 - 4494.56)</td><td align="center">0.96</td></tr><tr><td>300-mg</td><td align="center">15,235.13 (11,392.92&#x02013;19,077.34)</td><td align="center">15,312.29 (11,615.23 - 19,009.35)</td><td align="center">1.00</td></tr><tr><td>450-mg</td><td align="center">21,051.64 (18,233.17&#x02013;23,870.10)</td><td align="center">20,693.28 (19,477.42 - 21,909.14)</td><td align="center">0.98</td></tr><tr><td>450-mg twice day</td><td align="center">30,443.09 (24,553.06&#x02013;36,333.12)</td><td align="center">32,251.41 (26,029.38 - 38,473.43)</td><td align="center">1.06</td></tr></tbody></table><table-wrap-foot><fn><p>Results reported as <italic>M</italic> and lower to upper 95% (<italic>CI</italic>).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0070" position="float"><label>Table 14</label><caption><p><italic>Experiment 2,</italic> MET 2 Pharmacokinetic parameters: <italic>C</italic><sub><italic>min</italic></sub> (ng/mL) by dose/treatment and day.</p></caption><alt-text id="at0070">Table 14</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Dose GET73</th><th align="center">Day 1 - single dose (ng/mL)</th><th align="center">Day 14 - repeated doses (ng/mL)</th></tr></thead><tbody><tr><td>100-mg</td><td align="center">0 (0&#x02013;0)</td><td align="center">0 (0&#x02013;0)</td></tr><tr><td>300-mg</td><td align="center">0 (0&#x02013;0)</td><td align="center">0 (0 to 0)</td></tr><tr><td>450-mg</td><td align="center">0 (0&#x02013;0)</td><td align="center">0 (0&#x02013;0)</td></tr><tr><td>450-mg twice day</td><td align="center">804.43 (&#x02212;240.21 to 1849.08)</td><td align="center">426.58 (85.56&#x02013;767.71)</td></tr></tbody></table><table-wrap-foot><fn><p>Results reported as <italic>M</italic> and lower to upper 95% (<italic>CI</italic>).</p></fn></table-wrap-foot></table-wrap></p><p id="p0035">In <xref rid="t0005" ref-type="table">Table 1</xref>, <xref rid="t0010" ref-type="table">Table 2</xref>, timetables were set for the administration of GET 73 and the collection of data for the safety and tolerability of GET 73 in single and repeated ascending doses in healthy male volunteers.</p><p id="p0040">In <xref rid="t0020" ref-type="table">Tables 3 and 4</xref>, a procedure was documented for both single and repeated ascending doses with the goal of collecting preliminary pharmacokinetic data and monitor the safety of participants.</p><p id="p0045"><xref rid="t0025" ref-type="table">Table 5</xref> lists laboratory assessments for safety of GET 73 and potential factors that can affect its tolerability. Some tests were also used for inclusion/exclusion criteria (urine tests for drugs of abuse).</p><p id="p0050"><xref rid="t0030" ref-type="table">Table 6</xref> data shows the extent of exposure of GET 73 plasma concentration in a single ascending dose. <italic>C</italic><sub><italic>max</italic></sub> and <italic>AUC</italic><sub><italic>0-t</italic></sub> are measures of these factors respectively with <italic>t</italic><sub><italic>max</italic></sub> as a reference to the maximum concentration of GET 73 in the plasma.</p><p id="p0055"><xref rid="t0035" ref-type="table">Table 7</xref> tests for <italic>C</italic><sub><italic>max</italic></sub> in repeated ascending dose administration with data for Day 1 and Day 14.</p><p id="p0060">For <xref rid="t0040" ref-type="table">Table 8</xref>, <italic>t</italic><sub><italic>max</italic></sub> was collected in reference to when the <italic>C</italic><sub><italic>max</italic></sub> was reached in the repeated ascending dose administration group for both Day 1 and Day 14.</p><p id="p0065"><xref rid="t0045" ref-type="table">Table 9</xref> measures the <italic>AUC</italic><sub><italic>0-t</italic></sub> for repeated ascending dose administration experiment. <italic>AUC</italic><sub><italic>0-t</italic></sub> ratio compares Day 14 to Day 1 levels.</p><p id="p0070"><xref rid="t0050" ref-type="table">Table 10</xref> shows the <italic>C</italic><sub><italic>min</italic></sub> of GET 73 in the plasma over the repeated ascending dose administration. Data reported for Day 1 and Day 14.</p><p id="p0075"><xref rid="t0055" ref-type="table">Table 11</xref> goes into data about MET 2, the main metabolite of GET 73. Data reported for Day 1 and Day 14.</p><p id="p0080"><xref rid="t0060" ref-type="table">Table 12</xref> shows the <italic>t</italic><sub><italic>max</italic></sub> of MET 2 in the repeated ascending dose administration of GET 73.</p><p id="p0085">Data reported for Day 1 and Day 14.</p><p id="p0090"><xref rid="t0065" ref-type="table">Table 13</xref> collects data on the <italic>AUC</italic><sub><italic>0-t</italic></sub> of MET 2 in the plasma after repeated ascending dose administration of GET 73. Ratio compares Day 14 and Day 1 data are listed as well.</p><p id="p0095"><xref rid="t0070" ref-type="table">Table 14</xref> measures the <italic>C</italic><sub><italic>min</italic></sub> of MET 2 in the plasma for repeated ascending dose administration of GET 73. Data was collected for Day 14 and Day</p></sec><sec id="s0010"><label>2</label><title>Experimental design, materials and methods</title><p id="p0100">The method for collection of pharmacokinetic analytical data was validated at Quotient Bioresearch Ltd, UK. The procedures for the development and the validation of the method were based on the United States (US) Food and Drug Administration (FDA) recommendations Guidance for Industry Bioanalytical Method Validation - U.S. Department of Health and Human Services, FDA Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), May 2001, BP.</p><p id="p0105">Blood samples for pharmacokinetic evaluation in plasma were collected into tubes containing lithium heparin prior to dosing and at various time points after dosing up to 48&#x000a0;h for <italic>Experiment 1</italic> and up to 360&#x000a0;h for <italic>Experiment</italic>
<italic>2</italic>. The plasma samples were obtained from individuals from six single ascending dose groups in <italic>Experiment 1</italic> (10-mg, 30-mg, 100-mg, 300-mg, 450-mg and 600-mg) and four multiple ascending dose groups in <italic>Experiment 2</italic> (100-mg 300-mg, 450-mg and 450-mg twice a day).</p><p id="p0110">Concentrations of GET 73 in human plasma samples were measured by LC&#x02013;MS/MS after SLE+ (supported liquid extraction) over the calibration range of 2&#x02013;1000&#x000a0;ng/ml according to the validated method and the relevant SOPs. Concentrations of MET 2 in human plasma samples were measured by LC&#x02013;MS/MS after protein precipitation and dilution over the calibration range of 20&#x02013;10,000&#x000a0;ng/ml. All instrument control, data collection, peak area integration and storage were performed using Analyst (versions 1.4.2 and 1.5.1, Applied Biosystems Inc., OA, US). Peak areas were then imported into Watson LIMS (version 7.2 Thermo Fisher Scientific Inc., MA, US) for regression and quantification. The mass spectrometer response (peak area ratio of analyte to internal standard) of each calibration standard was calculated by Watson LIMS and plotted against the nominal (prepared) concentration. A weighted linear regression analysis was used to calculate an equation of the calibration line. Concentrations of GET 73 and MET 2 in the plasma samples were back calculated from the calibration lines.</p><p id="p0115">Values for the following pharmacokinetic parameters were estimated: 1) maximum plasma concentration (<italic>C</italic><sub><italic>max</italic></sub>), 2) the time to reach maximum plasma concentration (<italic>t</italic><sub><italic>max</italic></sub>) and 3) the area under the plasma concentration time curve over the dosing interval (<italic>AUC</italic><sub><italic>(0-t)</italic></sub>). Pharmacokinetic parameters were derived by noncompartmental analysis using WinNonlin (Version 4.1b, Pharshight Corporation, Mountain View, CA, US). Data in this article has not been published elsewhere.</p></sec></body><back><ref-list id="bibliog0005"><title>Referenfces</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sbref1"><person-group person-group-type="author"><name><surname>Haass-Koffler</surname><given-names>C.L.</given-names></name><name><surname>Goodyear</surname><given-names>K.</given-names></name><name><surname>Long</surname><given-names>V.M.</given-names></name><name><surname>Tran</surname><given-names>H.H.</given-names></name><name><surname>Loche</surname><given-names>A.</given-names></name><name><surname>Cacciaglia</surname><given-names>R.</given-names></name><name><surname>Swift</surname><given-names>R.M.</given-names></name><name><surname>Leggio</surname><given-names>L.</given-names></name></person-group><article-title>A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers</article-title><source>Eur. J Pharm. Sci</source><volume>109</volume><year>2017</year><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">28778464</pub-id></element-citation></ref></ref-list><sec id="s0020" sec-type="supplementary-material"><label>Transparency document</label><title>Supplementary material</title><p id="p0130"><supplementary-material content-type="local-data" id="ec0005"><caption><p>Supplementary material</p></caption><media xlink:href="mmc1.pdf"/></supplementary-material></p></sec><ack id="ack0005"><title>Acknowledgements</title><p>The authors would like to thank Dr. Anthony Priestley, Dr. Disala Fernando and the research staff at LCG Bioscience, Cambridge, UK for the logistic support of the trial. This study was funded by <funding-source id="gs1">CT Laboratories</funding-source>, San Remo, Italy. RC and AL are employees of CT Laboratories. RMS has received consultant fees from CT Laboratories and travel and honoraria from D&#x00026;A Pharma and Lundbeck. The other authors report no biomedical financial interests or potential conflicts of interest.</p></ack><fn-group><fn id="s0015" fn-type="supplementary-material"><label>Transparency document</label><p id="p0125">Transparency data associated with this article can be found in the online version at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.dib.2017.09.018" id="ir0005">doi:10.1016/j.dib.2017.09.018</ext-link>.</p></fn></fn-group></back></article>